Mary Jane Hinrichs

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina et al. · Cancer Cell · 2016 · 375 citations · Full text

Drug Targeting, Her2-targeted Therapy, Medicine +10

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics

Pamela Thompson, Ryan Fleming, Binyam Bezabeh et al. · Journal of Controlled Release · 2016 · 59 citations

Rational Design, Improved Stability, Medicine +9

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Johann S. de Bono, Mark T. Fleming, Judy S. Wang et al. · Clinical Cancer Research · 2021 · 48 citations · Full text

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Song Cho, Francesca Zammarchi, David G. Williams et al. · Molecular Cancer Therapeutics · 2018 · 46 citations

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

Jay Harper, Christopher Lloyd, Nazzareno Dimasi et al. · Molecular Cancer Therapeutics · 2017 · 45 citations · Full text